Vir Biotechnology, Inc. Fair Value Adjustment of Warrants
Vir Biotechnology, Inc. (VIR) reported Fair Value Adjustment of Warrants of $2.05 million for the 12-month period ending 2019-12-31, per its 10-K filed 2022-02-28.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2022-02-28
- Vir Biotechnology, Inc. fair value adjustment of warrants for the quarter ending 2019-12-31 was -$1.35M, a 919.39% decline year-over-year.
- Vir Biotechnology, Inc. fair value adjustment of warrants for the quarter ending 2019-09-30 was $2.62M.
- Vir Biotechnology, Inc. fair value adjustment of warrants for the quarter ending 2019-06-30 was $427.00K.
- Vir Biotechnology, Inc. fair value adjustment of warrants for the quarter ending 2019-03-31 was $357.00K.
- Vir Biotechnology, Inc. fair value adjustment of warrants for fiscal 2019 was $2.05M, a 2056.84% increase from fiscal 2018.
- Vir Biotechnology, Inc. fair value adjustment of warrants for fiscal 2018 was $95.00K.
- Vir Biotechnology, Inc. fair value adjustment of warrants for fiscal 2017 was -$82.00K.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2019-12-31 | -$1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.26M derived: sum of 2 quarters · filed 2022-02-28 | $1.69M derived: sum of 3 quarters · filed 2022-02-28 | $2.05M 10-K · filed 2022-02-28 |
| 2019-09-30 | $2.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $3.04M derived: sum of 2 quarters · filed 2020-11-10 | $3.40M 10-Q · filed 2020-11-10 | $3.57M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $427.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $784.00K 10-Q · filed 2020-08-11 | $949.00K derived: sum of 3 quarters · filed 2021-02-25 | |
| 2019-03-31 | $357.00K 10-Q · filed 2020-05-12 | $522.00K derived: sum of 2 quarters · filed 2021-02-25 | ||
| 2018-12-31 | $165.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $95.00K 10-K · filed 2021-02-25 | ||
| 2018-09-30 | -$70.00K 10-Q · filed 2019-11-19 | |||
| 2017-12-31 | -$82.00K 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |